High-intensity Focused Ultrasound Combined With Novel Hormone Therapy in Advanced Prostate Cancer (NCT07126093) | Clinical Trial Compass
Not Yet RecruitingNot Applicable
High-intensity Focused Ultrasound Combined With Novel Hormone Therapy in Advanced Prostate Cancer
134 participantsStarted 2025-10-01
Plain-language summary
The goal of this clinical trial is to explore the feasibility and the synergistic anti-cancer effect of high-intensity focused ultrasound (HIFU) combined with novel hormone therapy (NHT) in advanced prostate cancer (PCa). The main questions it aims to answer are: (1) whether could HIFU combined with NHT improve the long-term survival of patients with advanced PCa and alleviate local symptoms? (2) Does the synergistic effect of HIFU combined with NHT exist? Researchers will compare HIFU combined with NHT to NHT alone in advanced PCa patients. Participants will receive HIFU before NHT therapy or only receive NHT. In addition, participants are encouraged to record local symptoms condition and conduct regular follow-up.
Who can participate
Age range18 Years – 100 Years
SexMALE
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Inclusion criteria
✓. Male patients who are at least 18 years old;
✓. The physical condition score of the Eastern Cooperative Oncology Group (ECOG) in the United States is 0 to 2 points.
✓. Newly diagnosed patients with advanced prostate cancer confirmed by PSMA PET/CT (including metastatic hormone-sensitive prostate cancer or inoperable locally advanced prostate cancer);
✓. No previous treatments for prostate cancer have been received;
✓. After assessment, there was no obvious insufficiency of vital organs.
✓. Sign the written informed consent form for this study, indicating that they fully understand the purpose and process of this study and are willing to participate in it.
Exclusion criteria
✕. A history of any other active malignant tumor within 2 years (excluding well-treated basal cell or squamous cell skin cancer, superficial bladder cancer, or any other carcinoma in situ currently in complete remission);
Timeframe: From date of randomization until the date of first documented progression or date of death from any cause, whichever came first, assessed up to 80 months
Trial details
NCT IDNCT07126093
SponsorShanghai General Hospital, Shanghai Jiao Tong University School of Medicine
✕. Accompanied by severe comorbidities, immunosuppression, severe mental illness, severe activity limitation and other conditions that prevent compliance with clinical trials;
✕. Currently participating in other clinical trials related to this disease;
✕. According to the researcher's judgment, there are relevant evaluations that do not align with the best interests of the subjects' participation in the study (such as affecting the subjects' sense of happiness) or may hinder, restrict or interfere with the research protocol;
✕. Concurrent infectious diseases that affect the treatment outcome.